FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897977935> ?p ?o ?g. }

• W2897977935 endingPage "1146" @default.
• W2897977935 startingPage "1142" @default.
• W2897977935 abstract "Abstract Tisagenlecleucel (Kymriah; Novartis Pharmaceuticals) is a CD19-directed genetically modified autologous T-cell immunotherapy. On August 30, 2017, the FDA approved tisagenlecleucel for treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory in second or later relapse. Approval was based on the complete remission (CR) rate, durability of CR, and minimal residual disease (MRD) &lt;0.01% in a cohort of 63 children and young adults with relapsed or refractory ALL treated on a single-arm trial (CCTL019B2202). Treatment consisted of fludarabine and cyclophosphamide followed 2 to 14 days later by a single dose of tisagenlecleucel. The CR rate was 63% (95% confidence interval, 50%–75%), and all CRs had MRD &lt;0.01%. With a median follow-up of 4.8 months, the median duration of response was not reached. Cytokine release syndrome (79%) and neurologic events (65%) were serious toxicities reported in the trial. With implementation of a Risk Evaluation and Mitigation Strategy, the benefit–risk profile was considered acceptable for this patient population with such resistant ALL. A study of safety with 15 years of follow-up is required as a condition of the approval. See related commentary by Geyer, p. 1133" @default.
• W2897977935 created "2018-10-26" @default.
• W2897977935 creator A5018767367 @default.
• W2897977935 creator A5020286464 @default.
• W2897977935 creator A5035424351 @default.
• W2897977935 creator A5036413372 @default.
• W2897977935 creator A5037939650 @default.
• W2897977935 creator A5046524629 @default.
• W2897977935 creator A5051520990 @default.
• W2897977935 creator A5061115544 @default.
• W2897977935 creator A5066528744 @default.
• W2897977935 creator A5069297078 @default.
• W2897977935 creator A5074591130 @default.
• W2897977935 creator A5075249833 @default.
• W2897977935 creator A5090688476 @default.
• W2897977935 date "2019-02-15" @default.
• W2897977935 modified "2023-10-16" @default.
• W2897977935 title "FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia" @default.
• W2897977935 cites W2037522752 @default.
• W2897977935 cites W2069637569 @default.
• W2897977935 cites W2137440275 @default.
• W2897977935 cites W2143034151 @default.
• W2897977935 cites W2145985838 @default.
• W2897977935 cites W2516611622 @default.
• W2897977935 cites W2588300170 @default.
• W2897977935 cites W2752517775 @default.
• W2897977935 cites W2787301955 @default.
• W2897977935 doi "https://doi.org/10.1158/1078-0432.ccr-18-2035" @default.
• W2897977935 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30309857" @default.
• W2897977935 hasPublicationYear "2019" @default.
• W2897977935 type Work @default.
• W2897977935 sameAs 2897977935 @default.
• W2897977935 citedByCount "158" @default.
• W2897977935 countsByYear W28979779352019 @default.
• W2897977935 countsByYear W28979779352020 @default.
• W2897977935 countsByYear W28979779352021 @default.
• W2897977935 countsByYear W28979779352022 @default.
• W2897977935 countsByYear W28979779352023 @default.
• W2897977935 crossrefType "journal-article" @default.
• W2897977935 hasAuthorship W2897977935A5018767367 @default.
• W2897977935 hasAuthorship W2897977935A5020286464 @default.
• W2897977935 hasAuthorship W2897977935A5035424351 @default.
• W2897977935 hasAuthorship W2897977935A5036413372 @default.
• W2897977935 hasAuthorship W2897977935A5037939650 @default.
• W2897977935 hasAuthorship W2897977935A5046524629 @default.
• W2897977935 hasAuthorship W2897977935A5051520990 @default.
• W2897977935 hasAuthorship W2897977935A5061115544 @default.
• W2897977935 hasAuthorship W2897977935A5066528744 @default.
• W2897977935 hasAuthorship W2897977935A5069297078 @default.
• W2897977935 hasAuthorship W2897977935A5074591130 @default.
• W2897977935 hasAuthorship W2897977935A5075249833 @default.
• W2897977935 hasAuthorship W2897977935A5090688476 @default.
• W2897977935 hasBestOaLocation W28979779351 @default.
• W2897977935 hasConcept C121332964 @default.
• W2897977935 hasConcept C121608353 @default.
• W2897977935 hasConcept C126322002 @default.
• W2897977935 hasConcept C142424586 @default.
• W2897977935 hasConcept C143998085 @default.
• W2897977935 hasConcept C2776694085 @default.
• W2897977935 hasConcept C2776755627 @default.
• W2897977935 hasConcept C2777701055 @default.
• W2897977935 hasConcept C2778020697 @default.
• W2897977935 hasConcept C2778461978 @default.
• W2897977935 hasConcept C2779263901 @default.
• W2897977935 hasConcept C2779823535 @default.
• W2897977935 hasConcept C2780850621 @default.
• W2897977935 hasConcept C2908647359 @default.
• W2897977935 hasConcept C2909962599 @default.
• W2897977935 hasConcept C3875195 @default.
• W2897977935 hasConcept C71924100 @default.
• W2897977935 hasConcept C87355193 @default.
• W2897977935 hasConcept C99454951 @default.
• W2897977935 hasConceptScore W2897977935C121332964 @default.
• W2897977935 hasConceptScore W2897977935C121608353 @default.
• W2897977935 hasConceptScore W2897977935C126322002 @default.
• W2897977935 hasConceptScore W2897977935C142424586 @default.
• W2897977935 hasConceptScore W2897977935C143998085 @default.
• W2897977935 hasConceptScore W2897977935C2776694085 @default.
• W2897977935 hasConceptScore W2897977935C2776755627 @default.
• W2897977935 hasConceptScore W2897977935C2777701055 @default.
• W2897977935 hasConceptScore W2897977935C2778020697 @default.
• W2897977935 hasConceptScore W2897977935C2778461978 @default.
• W2897977935 hasConceptScore W2897977935C2779263901 @default.
• W2897977935 hasConceptScore W2897977935C2779823535 @default.
• W2897977935 hasConceptScore W2897977935C2780850621 @default.
• W2897977935 hasConceptScore W2897977935C2908647359 @default.
• W2897977935 hasConceptScore W2897977935C2909962599 @default.
• W2897977935 hasConceptScore W2897977935C3875195 @default.
• W2897977935 hasConceptScore W2897977935C71924100 @default.
• W2897977935 hasConceptScore W2897977935C87355193 @default.
• W2897977935 hasConceptScore W2897977935C99454951 @default.
• W2897977935 hasFunder F4320310388 @default.
• W2897977935 hasIssue "4" @default.
• W2897977935 hasLocation W28979779351 @default.
• W2897977935 hasLocation W28979779352 @default.
• W2897977935 hasOpenAccess W2897977935 @default.
• W2897977935 hasPrimaryLocation W28979779351 @default.
• W2897977935 hasRelatedWork W2085877601 @default.

• next